USANA Health Sciences (USNA) released earnings for second quarter that decreased from the same period last year and missed the Street estimates.The company's bottom line totaled $10.43 million, or $0.54 per share. This compares with $17.29 million, or $0.89 per share, in last year's second quarter.Analysts on average had expected the company to earn $0.65 per share, according to figures compiled by Thomson Reuters.

USANA Health Sciences（USNA）公布了第二季度的收益，与去年同期相比有所下降，未达到市场预期。该公司的总利润为1043万美元，即每股0.54美元。相比之下，去年第二季度为1729万美元，即每股0.89美元。根据汤森路透社（ThomsonReuters）编制的数据，分析师平均预期该公司每股收益为0.65美元。

Analysts' estimates typically exclude special items.The company's revenue for the quarter fell 10.6% to $212.87 million from $238.20 million last year..

。该公司本季度收入从去年的2.3820亿美元下降到2.1287亿美元，下降了10.6%。。

USANA Health Sciences earnings at a glance (GAAP) :-Earnings (Q2): $10.43 Mln. vs. $17.29 Mln. last year.-EPS (Q2): $0.54 vs. $0.89 last year.-Revenue (Q2): $212.87 Mln vs. $238.20 Mln last year. -Guidance:Full year EPS guidance: $2.40 - $2.55Full year revenue guidance: $850 - $880 Mln For comments and feedback contact: editorial@rttnews.com.

USANA Health Sciences收益概览（GAAP）：-收益（第二季度）：1043万美元。对比1729万美元。去年-每股收益（第二季度）：0.54美元，去年为0.89美元-收入（第二季度）：2.128亿美元，去年为2.382亿美元-指导：全年EPS指导：2.40-2.55美元全年收入指导：8.5-8.8亿美元评论和反馈联系：editorial@rttnews.com.

Biotech Stocks Facing FDA Decision In June 2024

2024年6月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision In April 2024

2024年4月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision in March 2024

2024年3月美国食品和药物管理局（FDA）决定生物技术股